Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) EPS (Basic) (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed EPS (Basic) for 13 consecutive years, with $0.07 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Basic) rose 126.92% to $0.07 in Q3 2025 year-over-year; TTM through Sep 2025 was $0.55, a 154.46% increase, with the full-year FY2024 number at -$1.15, changed N/A from a year prior.
  • EPS (Basic) was $0.07 for Q3 2025 at Theravance Biopharma, down from $1.09 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $12.14 in Q3 2022 to a low of -$1.24 in Q1 2021.
  • A 5-year average of $0.43 and a median of -$0.28 in 2023 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): skyrocketed 2629.17% in 2022, then tumbled 101.4% in 2023.
  • Theravance Biopharma's EPS (Basic) stood at -$0.48 in 2021, then surged by 68.75% to -$0.15 in 2022, then decreased by 13.33% to -$0.17 in 2023, then plummeted by 100.0% to -$0.34 in 2024, then skyrocketed by 120.59% to $0.07 in 2025.
  • Per Business Quant, the three most recent readings for TBPH's EPS (Basic) are $0.07 (Q3 2025), $1.09 (Q2 2025), and -$0.27 (Q1 2025).